Merck (MRK) announced the completion of the Verona Pharma (VRNA) acquisition. Verona Pharma is now a wholly-owned subsidiary of Merck and the American Depositary Shares of Verona Pharma will no longer be listed or traded on the Nasdaq Global Market.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Verona gets England, Wales high court approval for acquisition by Merck
- Merck initiates three Phase 2b trials evaluating tulisokibart
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- Trump Weekly: White House announces drug pricing deal with Pfizer
- Closing Bell Movers: Bentley Systems up 5% on S&P MidCap 400 entry